Vyome Holdings, Inc.
RSLSNASDAQHealthcare·US · USD
$2.16
+0.05 (+2.37%)
Close · 2026-06-26Price
Key statistics
Valuation
Market cap5.15M USD
Enterprise value9.19M USD
Trailing P/E0.01
Forward P/E-10.89
PEG ratio-0.00
Price / sales1.30
Price / book0.01
Profitability
Gross margin61.19%
Operating margin-165.23%
Profit margin-48.26%
Return on assets-53.50%
Return on equity-120.16%
Income (TTM)
Revenue7.17M USD
Gross profit4.57M USD
EBITDA-6.28M USD
Net income-3.46M USD
Diluted EPS-$830.44
Rev. growth (YoY)-42.70%
Balance sheet
Total cash2.52M USD
Total debt130.00K USD
Debt / equity10.57
Current ratio1.53
Book value / share-$8.67
Cash flow (TTM)
Operating cash flow-4.47M USD
Levered free cash flow-1.48M USD
Shares & price
Shares outstanding451.05K
Float737.81K
Held by institutions1.35%
Beta1.90
50-day MA$10.51
200-day MA$187.03
52-week high$18.60
52-week low$1.75
Dividends
- Forward rate
- $0.00
- Yield
- 0.00%
- Payout ratio
- 0.00%
- Frequency
- Unknown
Earnings (EPS)
DateEst.ActualSurprise2025-04-04—-2.47—2025-02-13-145.00-77.75+46.38%
About Vyome Holdings, Inc.
Vyome Holdings, Inc. is a clinical-stage biotechnology and specialty pharmaceutical company focused on developing next-generation therapeutic solutions for immuno-inflammatory diseases, including rare conditions with unmet medical needs. Operating within the healthcare sector under diversified biopharmaceuticals, the company engages in research and development of innovative pharmaceutical products. Vyome Holdings aims to address challenging diseases through advanced therapies, contributing to medical progress in immunology and rare disease treatment.
- Sector
- Healthcare
- Industry
- Medical Devices
- CEO
- Mr. Paul F. Hickey
- Employees
- 17
- Headquarters
- Irvine, CA, United States
- Website
- www.reshapelifesciences.com